Stock Movers AT&T Rises, Eli Lilly Jumps, AMD Higher After IBM Partnership
Aug 26, 2025
AT&T's shares surged after its $23 billion acquisition of spectrum licenses, bolstering its 5G capabilities. Eli Lilly's groundbreaking obesity pill trial thrilled investors with impressive weight loss results after earlier disappointments. Meanwhile, AMD's stock climbed following its partnership with IBM, focusing on innovative quantum computing architectures. The collaboration aims to showcase how quantum and classical computing can work together, marking a significant step forward in technology.
AI Snips
Chapters
Transcript
Episode notes
AT&T Boosts 5G Reach With Big Spectrum Purchase
- AT&T will buy spectrum licenses from EchoStar for about $23 billion to strengthen 5G and fiber delivery across the US.
- Bloomberg reported regulators pushed EchoStar to sell airwaves it hadn't used, which likely prompted this deal.
Lilly's Obesity Drug Shows Stronger Second Trial
- Eli Lilly's experimental obesity pill produced 9.6% body weight loss in a second trial and improved investor sentiment after a weaker first read.
- The data positions Lilly to file for regulatory approval by year-end with possible pharmacy availability in 2026.
AMD And IBM Team Up On Quantum-Centric Supercomputing
- AMD plans to partner with IBM to develop quantum-centric supercomputing combining quantum and high-performance computing, with a demo planned this year.
- Analysts reacted positively, with Truist upgrading AMD and raising its price target substantially above current levels.